AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of “Moderate Buy” by Analysts

AtriCure, Inc. (NASDAQ:ATRC) has received an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $52.4444.

A number of research analysts have recently commented on ATRC shares. Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. JPMorgan Chase & Co. boosted their target price on AtriCure from $42.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th.

AtriCure Trading Up 0.1%

Shares of AtriCure stock opened at $40.59 on Thursday. The company’s 50-day moving average price is $36.68 and its 200-day moving average price is $35.07. The company has a current ratio of 3.87, a quick ratio of 2.85 and a debt-to-equity ratio of 0.15. AtriCure has a 12-month low of $28.29 and a 12-month high of $43.11. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -66.53 and a beta of 1.47.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.10. The company had revenue of $134.27 million during the quarter, compared to analysts’ expectations of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. AtriCure’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, equities analysts expect that AtriCure will post -0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AtriCure news, Director Maggie Yuen sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $35.72, for a total value of $107,160.00. Following the completion of the transaction, the director owned 11,371 shares of the company’s stock, valued at $406,172.12. The trade was a 20.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sven Wehrwein sold 5,033 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $37.32, for a total transaction of $187,831.56. Following the completion of the transaction, the director directly owned 34,374 shares in the company, valued at $1,282,837.68. The trade was a 12.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 18,166 shares of company stock worth $676,378. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oberweis Asset Management Inc. bought a new position in AtriCure in the third quarter valued at $5,411,000. Voloridge Investment Management LLC boosted its holdings in shares of AtriCure by 1.5% in the 3rd quarter. Voloridge Investment Management LLC now owns 273,749 shares of the medical device company’s stock worth $9,650,000 after purchasing an additional 4,041 shares in the last quarter. Verition Fund Management LLC boosted its holdings in shares of AtriCure by 126.8% in the 3rd quarter. Verition Fund Management LLC now owns 17,752 shares of the medical device company’s stock worth $626,000 after purchasing an additional 9,924 shares in the last quarter. Qube Research & Technologies Ltd increased its position in shares of AtriCure by 203.6% during the 3rd quarter. Qube Research & Technologies Ltd now owns 94,729 shares of the medical device company’s stock valued at $3,339,000 after purchasing an additional 63,531 shares during the last quarter. Finally, Focus Partners Wealth raised its holdings in shares of AtriCure by 10.1% during the 3rd quarter. Focus Partners Wealth now owns 19,880 shares of the medical device company’s stock valued at $691,000 after buying an additional 1,824 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.